Click here to close Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly. We suggest using a current version of Chrome, FireFox, or Safari.
XB-ART-34648
Cell 2004 Mar 19;1166:855-67. doi: 10.1016/s0092-8674(04)00215-6.
Show Gene links Show Anatomy links

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.

Wan PT , Garnett MJ , Roe SM , Lee S , Niculescu-Duvaz D , Good VM , Jones CM , Marshall CJ , Springer CJ , Barford D , Marais R , Cancer Genome Project .


???displayArticle.abstract???
Over 30 mutations of the B-RAF gene associated with human cancers have been identified, the majority of which are located within the kinase domain. Here we show that of 22 B-RAF mutants analyzed, 18 have elevated kinase activity and signal to ERK in vivo. Surprisingly, three mutants have reduced kinase activity towards MEK in vitro but, by activating C-RAF in vivo, signal to ERK in cells. The structures of wild type and oncogenic V599EB-RAF kinase domains in complex with the RAF inhibitor BAY43-9006 show that the activation segment is held in an inactive conformation by association with the P loop. The clustering of most mutations to these two regions suggests that disruption of this interaction converts B-RAF into its active conformation. The high activity mutants signal to ERK by directly phosphorylating MEK, whereas the impaired activity mutants stimulate MEK by activating endogenous C-RAF, possibly via an allosteric or transphosphorylation mechanism.

???displayArticle.pubmedLink??? 15035987
???displayArticle.link??? Cell


Species referenced: Xenopus
Genes referenced: braf mapk1 snrpe

References :
Hubbard, Oncogenic mutations in B-Raf: some losses yield gains. 2004, Pubmed